FOXO4 and FOXO4-DRI
$Preclinical senolytic concept; No human PK or steady-state model
FOXO4-DRI is a senolytic peptide concept designed to interfere with survival signaling in senescent cells. The goal is selective removal of damaged cells that resist apoptosis, not general stimulation.
Published support is preclinical and mechanistic. Cell and animal results do not establish human anti-aging efficacy, human safety, route, dose, half-life, or long-term risk. Understand that senolytic means cell-killing. Look for target engagement, tissue selectivity, immune effects, kidney/liver handling of cellular debris, and off-target apoptosis.
Classification details
- FOXO4-DRI is a D-retro-inverso peptide developed from work on the FOXO4-p53 interaction in senescent cells.
- FOXO4 is a human transcription factor. FOXO4-DRI is the engineered peptide intended to interfere with one senescent-cell survival mechanism.
- FOXO4-DRI is a senolytic research peptide concept, not a general anti-aging supplement. It is designed to disrupt FOXO4-p53 interactions in senescent cells, which is a high-consequence biology target.
- The proposed mechanism is disruption of the FOXO4-p53 interaction.
- In the model, senescent cells use FOXO4 to keep p53 in a survival-associated nuclear state.
- FOXO4-DRI is proposed to release p53, allowing apoptosis of senescent cells.
- This is a preclinical mechanism, not a validated human rejuvenation protocol.
- The intended mechanism is selective apoptosis of senescent cells through transcription-factor interaction disruption. That makes specificity, delivery, and off-target cell death central questions.